⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 1, 2024Breast Cancer Targets and TherapyOpen Access

Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab

Qingqing Gu Mingzhi Zhu Yanyan Wang Yuanting Gu

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate the efficacy and safety of a pyrotinib-based therapy for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) in the real world.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gu et al. (2024) studied this question.

synapsesocial.com/papers/68e6c494b6db643587642c99 https://doi.org/10.2147/bctt.s457845

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and safety of pyrotinib-based regimens in HER2 positive metastatic breast cancer: A retrospective real-world data study2024 · 9 citations
2Final Efficacy and Safety Results of Pyrotinib Combined With Trastuzumab and Chemotherapy in Pre‐Treated Human Epidermal Growth Factor Receptor 2‐Positive Metastatic Breast CancerOriginal Research · 2026
3Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study2024 · 6 citations
4Survival analysis of pyrotinib in HER2-positive metastatic breast cancer: a multicenter real-world study2025 · 2 citations
5Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients2024 · 2 citations